Reaction
Meningitis Tuberculous reporting signals
As of the last recalculation, Meningitis Tuberculous appears in 556 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is PYRAZINAMIDE (PRR 427.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pyrazinamide | 90 | 427.8 | 431.9 |
| Ifosfamide | 119 | 263.5 | 265.0 |
| Isoniazid | 92 | 254.5 | 256.0 |
| Rifampicin | 49 | 198.7 | 199.7 |
| Filgrastim | 116 | 145.6 | 146.1 |
| Fludarabine Phosphate | 113 | 134.8 | 135.2 |
| Busulfan | 46 | 119.2 | 119.6 |
| Efavirenz | 27 | 95.2 | 95.5 |
| Vincristine Sulfate | 63 | 90.6 | 90.8 |
| Etoposide | 125 | 81.8 | 82.0 |
| Rifampin | 29 | 78.4 | 78.6 |
| Cisplatin | 115 | 69.2 | 69.3 |
| Doxorubicin Hydrochloride | 53 | 67.1 | 67.2 |
| Doxorubicin | 121 | 64.7 | 64.8 |
| Alemtuzumab | 29 | 59.2 | 59.3 |
| Methylprednisolone Acetate | 12 | 57.3 | 57.4 |
| Lamivudine Oral | 34 | 53.5 | 53.6 |
| Nevirapine | 12 | 50.9 | 50.9 |
| Carboplatin | 125 | 47.2 | 47.3 |
| Abacavir Sulfate | 12 | 47.1 | 47.2 |
| Lamivudine | 35 | 45.2 | 45.2 |
| Linezolid | 33 | 44.1 | 44.1 |
| Moxifloxacin | 16 | 43.7 | 43.8 |
| Rituximab | 142 | 33.4 | 33.5 |
| Moxifloxacin Hydrochloride | 17 | 32.3 | 32.4 |
| Zidovudine | 11 | 31.4 | 31.4 |
| Tenofovir Disoproxil Fumarate Tablets | 7 | 30.7 | 30.7 |
| Cyclophosphamide Injection, Solution | 91 | 22.8 | 22.8 |
| Cyclophosphamide | 91 | 22.8 | 22.8 |
| Cyclophosphamide For Injection | 91 | 22.8 | 22.8 |
| Amikacin | 9 | 20.1 | 20.1 |